Search bioRxiv⌕ Search

Biology subjects

Mori, L.

Publications and source records attributed to Mori, L..

3 recordsLinked to original sources

Expanding the MR1 ligandome using chemical class-specific fragmentation and molecular networking

The identification and subsequent characterization of unknown analytes using mass spectrometry presents a long-standing challenge across many research fields, particularly when analyte levels are low and the compound class is underrepresented in mass spectral databases. We have developed a data analysis workflow for investigating classes of small molecules and demonstrated its application through the reanalysis of data collected to probe for modified nucleoside MR1-presented antigens. We reanalyzed the datasets to screen for additional classes of compounds within the MR1 ligandome using Compound Discoverer, a commercial software package designed for metabolomic analysis, featuring fragmentation filtering nodes, molecular networking, and spectral database searching. Our study identified two compound classes that bind to MR1. One class includes compounds characterized by the presence of a ribityl substructure and molecular formulas consistent with structural similarity to riboflavin, where the most abundant compound differs from riboflavin by two additional oxygen atoms and one fewer carbon atom. A second class comprises an adenosine monophosphate isomer and larger analytes that are putatively identified as consisting of di- and tri-covalently bound nucleotides. The application of our analytical approach to characterize the MR1 ligandome demonstrates the power of combining compound-class fragmentation, molecular networking, and mass spectral database searching in exploring receptor ligandomes and, more generally, identifying novel classes of compounds.

immunology↗

Dynamics of microcompartment formation at the mitosis-to-G1 transition

As cells exit mitosis and enter G1, mitotic chromosomes decompact and transcription is reestablished. Previously, Hi-C studies showed that essentially all interphase 3D genome features including A/B-compartments, TADs, and CTCF loops, are lost during mitosis. However, Hi-C remains insensitive to features such as microcompartments, nested focal interactions between cis-regulatory elements (CREs). We therefore applied Region Capture Micro-C to cells from mitosis to G1. Unexpectedly, we observe microcompartments in prometaphase, which further strengthen in ana/telophase before gradually weakening in G1. Loss of loop extrusion through condensin depletion differentially impacts microcompartments and large A/B-compartments, suggesting that they are partially distinct. Using polymer modeling, we show that microcompartment formation is favored by chromatin compaction and disfavored by loop extrusion activity, explaining why ana/telophase likely provides a particularly favorable environment. Our results suggest that CREs exhibit intrinsic homotypic affinity leading to microcompartment formation, which may explain transient transcriptional spiking observed upon mitotic exit.

biophysics↗

Nucleobase adduct-containing metabolites are MR1 ligands that stimulate self-reactive MR1T cells

MR1T lymphocytes are a recently identified population of T cells that recognize unknown self-antigens presented by the non-polymorphic MHC-I-related molecule, MR1. MR1T cells can kill tumor cells and modulate the functions of other immune cells with promising therapeutic applications. By integrating genetic, pharmacological and biochemical approaches we identified carbonyl stress and alterations of nucleobase metabolism in tumor target cells that promote recognition by MR1 T cells. We dissected these pathways and found that nucleobase adduct-containing metabolites are self-antigens stimulating MR1T cells. Several nucleobase adducts are presented by MR1 molecules and stimulate individual MR1T cells. Our data suggest that MR1T cells are surveyor of cellular metabolic alterations occurring in conditions of metabolic stress, such as cancer, and lay the groundwork for the development of novel HLA-unrestricted T cell-based therapies.

immunology↗